Brief India: Pharmaceuticals: IPM: grows 6.1% in Sep25 and 7.2% in Q2FY26 and more
In this briefing: Pharmaceuticals: IPM: grows 6.1% in Sep25 and 7.2% in Q2FY26 MCX: Riding the Bullion Wave. Maintain BUY Result Update: Avenue Supermarts Ltd. - 13 Th October, 2025 Pick of the Week: Ashok Leyland - 11th October, 2025 Rays Power Infra Pre-IPO Tearsheet 1. Pharmaceuticals: IPM: grows 6.1% in Sep25 and 7.2% in Q2FY26 As per IQVIA, IPM saw moderate growth for Sep25 at 6.1% YoY (vs 8.1% in Aug25), with 2.4% YoY decline in units The strong growth in cardiac, respiratory, and oncology was offset by muted growth in anti-infective, gastro, VMN, and pain For Q2FY26, IPM grew 7.2% YoY, with 1.7% decline in units. Content is external broker report sourced from online content aggregator through publicly available sources and is displayed below for general informational purposes only. Refer full disclaimer below. 2. MCX: Riding the Bullion Wave. Maintain BUY MCX continues to present a compelling growth story built on its earlier driversnew product launches, a robust product pipeline, tech upgrades, and rising participation As we had highlighted in our earlier report The new gold standard, gold and silver were expected to emerge as major contributors to options premium, and this trend is firmly on track and gaining strength Options premium ADTV has witnessed strong growth, jumping to ~INR 67bn in October 2025 vs INR 41bn in Q2FY25, led by surging gold and silver volumes, which now account for ~60% of total notional volume and ~30% of premium ADTV.